ProCE Banner Activity

CME

Addressing the Medical Need in CLL: How BTK Inhibitors Are Improving Outcomes

Multimedia
Watch this on-demand Webcast capturing a live CCO Webinar to learn more about the latest data on BTK inhibitors and how to integrate them into your clinical practice for optimal treatment of patients with CLL.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: December 08, 2020

Expiration: December 07, 2021

No longer available for credit.

Share

Faculty

Ian W. Flinn

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Susan M. O Brien

Susan M. O Brien, MD

Professor of Medicine
Department of Leukemia
University of Texas M.D. Anderson Cancer Center
Houston, Texas

John Pagel

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Target Audience

This program is intended for hematologists and other clinicians involved in the management of patients with chronic lymphocytic leukemia.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate differences among agents targeting BTK in terms of molecular characteristics, selectivity, preclinical data, approved indications, dosing, safety profile, and efficacy
  • Delineate the variables to be considered in selecting treatment for CLL including tumor characteristics such as biomarkers and patient characteristics and preferences
  • Describe clinical trial results providing evidence for the important role of BTK inhibitor–based combinations in first-line treatment of CLL, including phase II and phase III trials
  • Select patients most likely to benefit from continuous first-line treatment options and those patients most likely to benefit from time-limited first-line options
  • Plan optimal, individualized therapeutic strategies for patients CLL taking into consideration recent practice-changing clinical trial results
  • Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, quality of life, and continuation of treatment
  • Assess ongoing clinical trials evaluating currently available and emerging BTK inhibitors (and BTK inhibitor–based combinations) to aid clinical trial enrollment and predict new options in the clinic

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Ian W. Flinn, MD, PhD, has disclosed that Sarah Cannon has received consulting fees from AstraZeneca, BeiGene, Curio, Gilead Sciences, Iksuda, Nurix, Pharmacyclics, Roche, and TG Therapeutics and has received funds for research support paid to his institution from AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera, Celgene, Constellation, Curis, F. Hoffmann-La Roche, Forma, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity, Janssen, Juno, Karyopharm, Kite, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium, Triphase Research & Development, Unum, and Verastem.

Faculty Disclosure

Primary Author

Susan M. O Brien, MD

Professor of Medicine
Department of Leukemia
University of Texas M.D. Anderson Cancer Center
Houston, Texas

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

John Pagel, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, BeiGene, Gilead Sciences, and Loxo.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has disclosed that his spouse/partner has ownership interest (stock) in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen M Rosenthal, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 08, 2020, through December 07, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize the use of current and emerging therapeutic strategies in the care of their patients with chronic lymphocytic leukemia.